|
|
| | WX-671/Mesupron Basic information |
| Product Name: | WX-671/Mesupron | | Synonyms: | WX-671;WX-671/Mesupron;4-[(2S)-3-[3-[(Hydroxyamino)iminomethyl]phenyl]-1-oxo-2-[[[2,4,6-tris(1-methylethyl)phenyl]sulfonyl]amino]propyl]-1-piperazinecarboxylic acid ethyl ester;Mesupron(WX 671);UPAMOSTAT;HUASEDVYRABWCV-NDEPHWFRSA-N;Mesupron（Upamostat）;1-Piperazinecarboxylic acid, 4-[(2S)-3-[3-[(hydroxyamino)iminomethyl]phenyl]-1-oxo-2-[[[2,4,6-tris(1-methylethyl)phenyl]sulfonyl]amino]propyl]-, ethyl ester | | CAS: | 590368-25-5 | | MF: | C32H47N5O6S | | MW: | 629.81 | | EINECS: | | | Product Categories: | | | Mol File: | 590368-25-5.mol |  |
| | WX-671/Mesupron Chemical Properties |
| Boiling point | 761.3±70.0 °C(Predicted) | | density | 1.25 | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 250 mg/mL (396.95 mM) | | pka | 6.99±0.69(Predicted) |
| | WX-671/Mesupron Usage And Synthesis |
| Uses | WX 671 is the oral pro-drug of the active metabolite WX-UK1, a uPA inhibitor. |
| | WX-671/Mesupron Preparation Products And Raw materials |
|